Literature DB >> 31119480

Multisession radiosurgery for perioptic meningiomas: medium-to-long term results from a CyberKnife cooperative study.

Marcello Marchetti1, Alfredo Conti2,3, Giancarlo Beltramo4, Valentina Pinzi5, Antonio Pontoriero6, Irene Tramacere7, Carolin Senger8, Stefano Pergolizzi6, Laura Fariselli5.   

Abstract

PURPOSE: Most recent literature has confirmed the efficacy of single-session radiosurgery (sRS) in the treatment of intracranial meningioma. Unfortunately, sRS is not always applicable due to large tumor volume and the proximity of the tumor to critical structures. When sRS is not recommended, multi-session radiosurgery (mRS) can be the solution. The best treatment schedule for mRS, however, is not well established. The aim of the present retrospective study is to validate the effectiveness of one approach, 25 Gy delivered in 5 fractions in 5 consecutive days, to treat skull base meningiomas.
METHODS: This is a retrospective multicenter study. Patients with an anterior or a medium skull base meningioma that could not be treated by sRS due to large volume or proximity to the anterior optic pathways (AOPs) underwent 5-fraction mRS. Only patients with at least 36 months follow-up were included in the analysis. Local control and visual outcomes were investigated.
RESULTS: One-hundred-sixty-seven patients were included in the analysis. One-hundred-one patients underwent RS as a primary indication and 66 were treated after a previous surgery. The median follow-up period was 51 months (range 36-129 months). Progression-free survival at 3, 5 and 8 years were, respectively, 98%, 94% and 90%. Excluding the progressive disease patients, the visual worsening rate was 3.7%. The 42% of the patients with a pre-treatment visual deficit experienced improvement in vision.
CONCLUSION: 25 Gy delivered in 5 fractions is an effective modality for meningiomas that are near the AOP or are too large to be treated by sRS. The treatment schedule controlled the tumors while sparing visual function.

Entities:  

Keywords:  Meningiomas; Multisession radiosurgery; Optic pathways; Perioptic; Radiosurgery

Mesh:

Year:  2019        PMID: 31119480     DOI: 10.1007/s11060-019-03196-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  5 in total

1.  The long-term outcome of CyberKnife-based stereotactic radiotherapy for central skull base meningiomas: a single-center experience.

Authors:  Sukwoo Hong; Kengo Sato; Kenji Kagawa; Shunsuke Ichi
Journal:  Neurosurg Rev       Date:  2021-04-10       Impact factor: 3.042

2.  The "Combo" radiotherapy treatment for high-risk grade 2 meningiomas: dose escalation and initial safety and efficacy analysis.

Authors:  Antonio Pontoriero; Paola Critelli; Alfredo Conti; Salvatore Cardali; Filippo Flavio Angileri; Antonino Germanò; Sara Lillo; Alessandro Carretta; Anna Brogna; Anna Santacaterina; Silvana Parisi; Stefano Pergolizzi
Journal:  J Neurooncol       Date:  2022-08-04       Impact factor: 4.506

3.  Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM.

Authors:  Leor Zach; Amir Agami; Orit Furman; Moshe Attia; Zvi Cohen; Iris Ben-Bassat Mizrachi; Guy Tam; Zion Zibly; Ouzi Nissim; Roberto Spiegelmann; Ruth Huna-Baron
Journal:  Radiat Oncol       Date:  2021-08-28       Impact factor: 3.481

Review 4.  Advances in Multidisciplinary Management of Skull Base Meningiomas.

Authors:  Tamara Ius; Alessandro Tel; Giuseppe Minniti; Teresa Somma; Domenico Solari; Michele Longhi; Pasquale De Bonis; Alba Scerrati; Mario Caccese; Valeria Barresi; Alba Fiorentino; Leonardo Gorgoglione; Giuseppe Lombardi; Massimo Robiony
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

5.  EANO guideline on the diagnosis and management of meningiomas.

Authors:  Roland Goldbrunner; Pantelis Stavrinou; Michael D Jenkinson; Felix Sahm; Christian Mawrin; Damien C Weber; Matthias Preusser; Giuseppe Minniti; Morten Lund-Johansen; Florence Lefranc; Emanuel Houdart; Kita Sallabanda; Emilie Le Rhun; David Nieuwenhuizen; Ghazaleh Tabatabai; Riccardo Soffietti; Michael Weller
Journal:  Neuro Oncol       Date:  2021-11-02       Impact factor: 13.029

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.